quarta-feira, 1 de maio de 2013


STATE OF CALIFORNIA
ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986






CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY
19/abr/13






The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and republish at least once per year the list of chemicals known to the State to cause cancer or reproductive toxicity.  For easy reference, chemicals which are newly added are shown in underline.  Chemicals or endpoints shown in strikeout were placed on the Proposition 65 list on the date noted, and have subsequently been removed.  A hyperlink is provided for the basis for removing the chemical.
In the Listing Mechanism column, "AB" denotes authoritative bodies, "SQE" denotes State's Qualified Experts, "FR" denotes formally required to be labeled or identified, and "LC" denotes Labor Code.  For those chemicals for which the basis for listing documentation is available electronically, a hyperlink to the documentation is provided.  The identification number indicated in the following list is the Chemical Abstracts Service (CAS) Registry Number.  No CAS number is given when several substances are presented as a single listing.  The date refers to the initial appearance of the chemical on the list.  For those chemicals for which a no significant risk level (NSRL) for carcinogens or maximum allowable dose level (MADL) for reproductive toxicants has been adopted, it is denoted in the column, "NSRL or MADL."  For those NSRLs or MADLs for which the risk assessment documentation is available electronically, a hyperlink to the documentation is provided.







Chemical Type of Toxicity Listing Mechanism CAS No. Date Listed NSRL or MADL   (µg/day)a
           
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) cancer AB 26148-68-5 01/jan/90 2
Acetaldehyde cancer SQE 75-07-0 01/abr/88 90 (inhalation)
Acetamide cancer  AB 60-35-5 01/jan/90 10
Acetazolamide    developmental   FR 59-66-5 20/ago/99  
Acetochlor cancer SQE 34256-82-1 01/jan/89  
Acetohydroxamic acid developmental FR 546-88-3 01/abr/90  
2-Acetylaminofluorene cancer SQE 53-96-3 01/jul/87 0,2
Acifluorfen sodium cancer AB 62476-59-9 01/jan/90  
Acrylamide cancer AB 79-06-1 01/jan/90 0,2
Acrylamide developmental, male  AB 79-06-1 25/fev/11 140
Acrylonitrile cancer FR 107-13-1 01/jul/87 0,7
Actinomycin D cancer FR 50-76-0 01/out/89 0,00008
Actinomycin D developmental FR 50-76-0 01/out/92  
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide cancer SQE 3688-53-7 01/jul/87 3
Aflatoxins cancer SQE --- 01/jan/88  
Alachlor cancer SQE 15972-60-8 01/jan/89  
Alcoholic beverages, when associated with alcohol abuse cancer SQE --- 01/jul/88  
Aldrin cancer SQE 309-00-2 01/jul/88 0,04
All-trans retinoic acid developmental  SQE 302-79-4 01/jan/89  
Allyl chloride  Delisted October 29, 1999 [Click here for the basis for delisting] cancer AB 107-05-1 01/jan/90  
Alprazolam developmental  FR 28981-97-7 01/jul/90  
Altretamine developmental, male  FR 645-05-6 20/ago/99  
Amantadine hydrochloride developmental  FR 665-66-7 27/fev/01  
Amikacin sulfate developmental FR 39831-55-5 01/jul/90  
2-Aminoanthraquinone cancer LC 117-79-3 01/out/89 20
p-Aminoazobenzene cancer AB 60-09-3 01/jan/90  
o-Aminoazotoluene cancer SQE 97-56-3 01/jul/87 0,2
4-Aminobiphenyl (4-aminodiphenyl) cancer LC 92-67-1 27/fev/87 0,03
1-Amino-2,4-dibromoanthraquinone cancer  AB 81-49-2 26/ago/97  
3-Amino-9-ethylcarbazole hydrochloride cancer SQE 6109-97-3 01/jul/89 9
2-Aminofluorene cancer  SQE 153-78-6 29/jan/99  
Aminoglutethimide developmental FR 125-84-8 01/jul/90  
Aminoglycosides developmental  FR --- 01/out/92  
1-Amino-2-methylanthraquinone cancer LC 82-28-0 01/out/89 5
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole cancer SQE 712-68-5 01/jul/87 0,04
4-Amino-2-nitrophenol cancer  SQE 119-34-6 29/jan/99  
Aminopterin developmental, female SQE 54-62-6 01/jul/87  
Amiodarone hydrochloride developmental, female, male  FR 19774-82-4 26/ago/97  
Amitraz developmental  AB 33089-61-1 30/mar/99  
Amitrole cancer SQE 61-82-5 01/jul/87 0,7
Amoxapine developmental  FR 14028-44-5 15/mai/98  
Amsacrine cancer  LC 51264-14-3 07/ago/09  
tert-Amyl methyl ether developmental  LC 994-05-8 18/dez/09  
Anabolic steroids female, male FR --- 01/abr/90  
Analgesic mixtures containing Phenacetin cancer LC --- 27/fev/87  
Androstenedione cancer AB 63-05-8 03/mai/11  
Angiotensin converting enzyme  (ACE) inhibitors developmental FR --- 01/out/92  
Aniline cancer AB 62-53-3 01/jan/90 100
Aniline hydrochloride cancer  AB 142-04-1 15/mai/98  
o-Anisidine cancer SQE 90-04-0 01/jul/87 5
o-Anisidine hydrochloride cancer SQE 134-29-2 01/jul/87 7
Anisindione developmental FR 117-37-3 01/out/92  
Anthraquinone cancer  AB 84-65-1 28/set/07  
Antimony oxide (Antimony trioxide) cancer AB 1309-64-4 01/out/90  
Aramite cancer SQE 140-57-8 01/jul/87 20
Areca nut cancer  LC   --- 03/fev/06  
Aristolochic acids cancer  LC   --- 09/jul/04  
Arsenic (inorganic arsenic compounds) cancer LC -- 27/fev/87 0.06 (inhalation)              10 (except inhalation)
Arsenic (inorganic oxides) developmental SQE --- 01/mai/97  
Asbestos cancer LC 1332-21-4 27/fev/87 100 fibers/day (inhalation)
Aspirin (NOTE:  It is especially  important not to use aspirin during the last three months of pregnancy,  unless specifically directed to do so by a physician because it may cause  problems in the unborn child or  complications during delivery.) developmental, female SQE 50-78-2 01/jul/90  
Atenolol developmental  FR 29122-68-7 26/ago/97  
Auramine cancer SQE 492-80-8 01/jul/87 0,8
Auranofin developmental  FR 34031-32-8 29/jan/99  
Avermectin B1 (Abamectin) developmental AB 71751-41-2 03/dez/10 4,4
Azacitidine cancer AB 320-67-2 01/jan/92  
Azaserine cancer SQE 115-02-6 01/jul/87 0,06
Azathioprine cancer LC 446-86-6 27/fev/87 0,4
Azathioprine developmental FR 446-86-6 01/set/96  
Azobenzene cancer AB 103-33-3 01/jan/90 6
           
Barbiturates developmental FR --- 01/out/92  
Beclomethasone dipropionate developmental  FR 5534-09-8 15/mai/98  
Benomyl developmental, male SQE 17804-35-2 01/jul/91  
Benthiavalicarb-isopropyl cancer  AB 177406-68-7 01/jul/08  
Benz[a]anthracene cancer SQE 56-55-3 01/jul/87 0.033 (oral)
Benzene cancer LC 71-43-2 27/fev/87 6.4 (oral)                          13 (inhalation)
Benzene developmental, male  SQE 71-43-2 26/dez/97 24 (oral)                            49 (inhalation)
Benzidine [and its salts] cancer LC 92-87-5 27/fev/87 0,001
Benzidine-based dyes cancer FR --- 01/out/92  
Benzodiazepines developmental FR --- 01/out/92  
Benzo[b]fluoranthene cancer SQE 205-99-2 01/jul/87 0.096 (oral)
Benzo[j]fluoranthene cancer SQE 205-82-3 01/jul/87 0.11 (oral)
Benzo[k]fluoranthene cancer SQE 207-08-9 01/jul/87  
Benzofuran cancer AB 271-89-6 01/out/90 1,1
Benzophenone cancer LC 119-61-9 22/jun/12  
Benzo[a]pyrene cancer SQE 50-32-8 01/jul/87 0,06
Benzotrichloride cancer SQE 98-07-7 01/jul/87  
Benzphetamine hydrochloride developmental FR 5411-22-3 01/abr/90  
Benzyl chloride cancer AB 100-44-7 01/jan/90 4
Benzyl violet 4B cancer SQE 1694-09-3 01/jul/87 30
Beryllium and beryllium compounds cancer SQE --- 01/out/87  
   Beryllium          0,1
   Beryllium oxide         0,1
   Beryllium sulfate         0,0002
Betel quid with tobacco cancer AB --- 01/jan/90  
Betel quid without tobacco cancer  LC   --- 03/fev/06  
2,2-Bis(bromomethyl)-1,3-propanediol cancer AB 3296-90-0 01/mai/96  
Bis(2-chloroethyl)ether cancer SQE 111-44-4 01/abr/88 0,3
N,N-Bis(2-chloroethyl)-2-naphthylamine  (Chlornapazine) cancer LC 494-03-1 27/fev/87  
Bischloroethyl nitrosourea (BCNU) (Carmustine) cancer SQE 154-93-8 01/jul/87  
Bischloroethyl nitrosourea (BCNU) (Carmustine) developmental FR 154-93-8 01/jul/90  
Bis(chloromethyl)ether cancer LC 542-88-1 27/fev/87 0,02
Bis(2-chloro-1-methylethyl)ether,  technical grade cancer  SQE --- 29/out/99  
Bisphenol A (BPA)  Delisted April 19, 2013 developmental AB 80-05-7 11/abr/13  
Bitumens, extracts of steam-refined and air refined cancer AB --- 01/jan/90  
Bracken fern cancer AB --- 01/jan/90  
Bromacil lithium salt developmental  AB 53404-19-6 18/mai/99  
Bromacil lithium salt male  SQE 53404-19-6 17/jan/03  
Bromate cancer  AB 15541-45-4 31/mai/02  
Bromochloroacetic acid cancer  AB 5589-96-8 06/abr/10  
Bromodichloromethane cancer AB 75-27-4 01/jan/90 5
Bromoethane cancer AB 74-96-4 22/dez/00 96
Bromoform cancer AB 75-25-2 01/abr/91 64
1-Bromopropane (1-BP) developmental, female, male  AB 106-94-5 07/dez/04  
2-Bromopropane (2-BP) female, male  AB 75-26-3 31/mai/05  
Bromoxynil developmental FR 1689-84-5 01/out/90  
Bromoxynil octanoate developmental  AB 1689-99-2 18/mai/99  
Butabarbital sodium developmental FR 143-81-7 01/out/92  
1,3-Butadiene cancer SQE 106-99-0 01/abr/88 0,4
1,3-Butadiene developmental, female, male  AB 106-99-0 16/abr/04  
1,4-Butanediol dimethanesulfonate (Busulfan) cancer LC 55-98-1 27/fev/87  
1,4-Butanediol dimethanesulfonate (Busulfan) developmental SQE 55-98-1 01/jan/89  
Butylated hydroxyanisole cancer AB 25013-16-5 01/jan/90 4000
Butyl benzyl phthalate (BBP) developmental  AB 85-68-7 02/dez/05  
n-Butyl glycidyl ether male  LC 2426-08-6 07/ago/09  
beta-Butyrolactone cancer SQE 3068-88-0 01/jul/87 0,7
           
Cacodylic acid cancer AB 75-60-5 01/mai/96  
Cadmium developmental, male  SQE --- 01/mai/97 4.1 (oral)
Cadmium and cadmium compounds cancer SQE --- 01/out/87  
   Cadmium         0.05 (inhalation)
Caffeic acid cancer AB 331-39-5 01/out/94  
Captafol cancer SQE 2425-06-1 01/out/88 5
Captan cancer AB 133-06-2 01/jan/90 300
Carbamazepine developmental  FR 298-46-4 29/jan/99  
Carbaryl cancer  AB 63-25-2 05/fev/10  
Carbaryl developmental, male  LC 63-25-2 07/ago/09  
Carbazole cancer AB 86-74-8 01/mai/96 4,1
Carbon black (airborne, unbound particles of respirable size) cancer  AB 1333-86-4 21/fev/03  
Carbon disulfide developmental, female, male SQE 75-15-0 01/jul/89  
Carbon monoxide developmental SQE 630-08-0 01/jul/89  
Carbon tetrachloride cancer SQE 56-23-5 01/out/87 5
Carbon-black extracts cancer AB --- 01/jan/90  
Carboplatin developmental FR 41575-94-4 01/jul/90  
N-Carboxymethyl-N-nitrosourea cancer SQE 60391-92-6 25/jan/02 0,7
Catechol cancer  AB 120-80-9 15/jul/03  
Ceramic fibers (airborne particles of respirable size) cancer AB --- 01/jul/90  
Certain combined chemotherapy for lymphomas cancer LC --- 27/fev/87  
Chenodiol developmental FR 474-25-9 01/abr/90  
Chlorambucil cancer LC 305-03-3 27/fev/87 0,002
Chlorambucil developmental SQE 305-03-3 01/jan/89  
Chloramphenicol Delisted January 4, 2013 [Click here for the basis for delisting] cancer LC 56-75-7 01/out/89  
Chlorcyclizine hydrochloride developmental FR 1620-21-9 01/jul/87  
Chlordane cancer SQE 57-74-9 01/jul/88 0,5
Chlordecone (Kepone) cancer SQE 143-50-0 01/jan/88 0,04
Chlordecone (Kepone) developmental SQE 143-50-0 01/jan/89  
Chlordiazepoxide developmental FR 58-25-3 01/jan/92  
Chlordiazepoxide hydrochloride developmental FR 438-41-5 01/jan/92  
Chlordimeform cancer SQE 6164-98-3 01/jan/89  
Chlorendic acid cancer SQE 115-28-6 01/jul/89 8
Chlorinated paraffins (Average chain length, C12;approximately 60 percent chlorine by weight) cancer SQE 108171-26-2 01/jul/89 8
p-Chloroaniline cancer AB 106-47-8 01/out/94 1,5
p-Chloroaniline hydrochloride cancer  AB 20265-96-7 15/mai/98 1,9
Chlorodibromomethane  Delisted October 29, 1999 [Click here for the basis for delisting] cancer AB 124-48-1 01/jan/90  
Chloroethane (Ethyl chloride) cancer AB 75-00-3 01/jul/90 150
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) cancer SQE 13010-47-4 01/jan/88  
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) developmental FR 13010-47-4 01/jul/90  
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) cancer SQE 13909-09-6 01/out/88  
Chloroform cancer SQE 67-66-3 01/out/87 20 (oral)                            40 (inhalation)
Chloroform developmental  LC 67-66-3 07/ago/09  
Chloromethyl methyl ether (technical grade) cancer LC 107-30-2 27/fev/87 0,3
3-Chloro-2-methylpropene cancer SQE 563-47-3 01/jul/89 5
1-Chloro-4-nitrobenzene cancer SQE 100-00-5 29/out/99  
4-Chloro-o-phenylenediamine cancer SQE 95-83-0 01/jan/88 40
Chloroprene cancer  AB 126-99-8 02/jun/00  
2-Chloropropionic acid male  LC 598-78-7 07/ago/09  
Chlorothalonil cancer SQE 1897-45-6 01/jan/89 41
p-Chloro-o-toluidine cancer AB 95-69-2 01/jan/90 3
p-Chloro-o-toluidine, strong acid salts of cancer  AB --- 15/mai/98  
   p-Chloro-o-toluidine, hydrochloride         3,3
5-Chloro-o-toluidine and its strong acid salts cancer  SQE --- 24/out/97  
Chlorotrianisene cancer FR 569-57-3 01/set/96  
Chlorozotocin cancer AB 54749-90-5 01/jan/92 0,003
Chlorsulfuron [Click here for the basis for removal of male reproductive toxicity endpoint]  developmental, female, male  AB 64902-72-3 14/mai/99  
Chromium (hexavalent compounds) cancer LC --- 27/fev/87 0.001 (inhalation)
Chromium (hexavalent compounds) developmental, female, male  SQE  --- 19/dez/08 8.2 (oral)
Chrysene cancer AB 218-01-9 01/jan/90 0.35 (oral)
C.I. Acid Red 114 cancer AB 6459-94-5 01/jul/92  
C.I. Basic Red 9 monohydrochloride cancer SQE 569-61-9 01/jul/89 3
C.I. Direct Blue 15 cancer  AB 2429-74-5 26/ago/97  
C.I. Direct Blue 218 cancer  AB 28407-37-6 26/ago/97 50
C.I. Disperse Yellow 3 cancer SQE 2832-40-8 08/fev/13  
C.I. Solvent Yellow 14 cancer  AB 842-07-9 15/mai/98  
Ciclosporin (Cyclosporin A; Cyclosporine) cancer AB 59865-13-3; 79217-60-0 01/jan/92  
Cidofovir cancer, developmental, female, male FR 113852-37-2 29/jan/99  
Cinnamyl anthranilate cancer SQE 87-29-6 01/jul/89 200
Cisplatin cancer SQE 15663-27-1 01/out/88  
Citrus Red No. 2 cancer LC 6358-53-8 01/out/89  
Cladribine developmental FR 4291-63-8 01/set/96  
Clarithromycin developmental  FR 81103-11-9 01/mai/97  
Clobetasol propionate developmental, female  FR 25122-46-7 15/mai/98  
Clofibrate cancer FR 637-07-0 01/set/96  
Clomiphene citrate developmental FR 50-41-9 01/abr/90  
Clorazepate dipotassium developmental FR 57109-90-7 01/out/92  
Cobalt metal powder cancer AB 7440-48-4 01/jul/92  
Cobalt [II] oxide cancer AB 1307-96-6 01/jul/92  
Cobalt sulfate cancer  LC 10124-43-3 20/mai/05  
Cobalt sulfate heptahydrate cancer  AB 10026-24-1 02/jun/00  
Cocaine developmental, female SQE 50-36-2 01/jul/89  
Coconut oil diethanolamine condensate (cocamide diethanolamine) cancer LC 68603-42-9 22/jun/12  
Codeine phosphate developmental  FR 52-28-8 15/mai/98  
Coke oven emissions cancer LC --- 27/fev/87 0,3
Colchicine developmental, male FR 64-86-8 01/out/92  
Conjugated estrogens cancer LC --- 27/fev/87  
Conjugated estrogens developmental FR --- 01/abr/90  
Creosotes cancer SQE --- 01/out/88  
p-Cresidine cancer SQE 120-71-8 01/jan/88 5
Cumene cancer  AB 98-82-8 06/abr/10  
Cupferron cancer SQE 135-20-6 01/jan/88 3
Cyanazine developmental FR 21725-46-2 01/abr/90  
Cycasin cancer SQE 14901-08-7 01/jan/88  
Cycloate developmental  AB 1134-23-2 19/mar/99  
Cyclohexanol  Delisted January 25, 2002 [Click here for the basis for delisting] male  AB 108-93-0 06/nov/98  
Cycloheximide developmental FR 66-81-9 01/jan/89  
Cyclopenta[cd]pyrene cancer LC 27208-37-3 29/abr/11  
Cyclophosphamide (anhydrous) cancer LC 50-18-0 27/fev/87 1
Cyclophosphamide (anhydrous) developmental, female, male SQE - developmental    FR - female, male  50-18-0 01/jan/89  
Cyclophosphamide (hydrated) cancer LC 6055-19-2 27/fev/87 1
Cyclophosphamide (hydrated) developmental, female, male SQE - developmental     FR - female, male  6055-19-2 01/jan/89  
Cyhexatin developmental FR 13121-70-5 01/jan/89  
Cytarabine developmental SQE 147-94-4 01/jan/89  
Cytembena cancer  AB 21739-91-3 15/mai/98  
           
D&C Orange No. 17 cancer AB 3468-63-1 01/jul/90  
D&C Red No. 8 cancer AB 2092-56-0 01/out/90  
D&C Red No. 9 cancer AB 5160-02-1 01/jul/90 100
D&C Red No. 19 cancer AB 81-88-9 01/jul/90  
Dacarbazine cancer SQE 4342-03-4 01/jan/88 0,01
Dacarbazine developmental  FR 4342-03-4 29/jan/99  
Daminozide cancer AB 1596-84-5 01/jan/90 40
Danazol developmental FR 17230-88-5 01/abr/90  
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) cancer AB 117-10-2 01/jan/92 9
Daunomycin cancer SQE 20830-81-3 01/jan/88  
Daunorubicin hydrochloride  developmental FR 23541-50-6 01/jul/90  
2,4-D butyric acid [Click here for the basis for the removal of developmental toxicity endpoint] developmental,   male    AB 94-82-6 18/jun/99 910
DDD (Dichlorodiphenyl-dichloroethane) cancer SQE 72-54-8 01/jan/89 2                                      (DDT, DDE, DDD in combination)
DDE (Dichlorodiphenyl-dichloroethylene) cancer SQE 72-55-9 01/jan/89 2                                      (DDT, DDE, DDD in combination)
DDT (Dichlorodiphenyl-trichloroethane) cancer SQE 50-29-3 01/out/87 2                                      (DDT, DDE, DDD in combination)
o,p'-DDT developmental, female, male  AB 789-02-6 15/mai/98  
p,p'-DDT developmental, female, male  AB 50-29-3 15/mai/98  
DDVP (Dichlorvos) cancer SQE 62-73-7 01/jan/89 2
2,4-DP (dichloroprop)  Delisted January 25, 2002 [Click here for the basis for delisting] developmental  AB 120-36-5 27/abr/99  
Demeclocycline hydrochloride (internal use) developmental FR 64-73-3 01/jan/92  
N,N'-Diacetylbenzidine cancer LC 613-35-4 01/out/89  
2,4-Diaminoanisole cancer FR 615-05-4 01/out/90 30
2,4-Diaminoanisole sulfate cancer SQE 39156-41-7 01/jan/88 50
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline) cancer SQE 101-80-4 01/jan/88 5
2,4-Diaminotoluene cancer SQE 95-80-7 01/jan/88 0,2
Diaminotoluene (mixed) cancer AB --- 01/jan/90  
Diazepam developmental FR 439-14-5 01/jan/92  
Diazoaminobenzene cancer  LC 136-35-6 20/mai/05  
Diazoxide developmental  FR 364-98-7 27/fev/01  
Dibenz[a,h]acridine cancer SQE 226-36-8 01/jan/88  
Dibenz[a,j]acridine cancer SQE 224-42-0 01/jan/88  
Dibenz[a,h]anthracene cancer SQE 53-70-3 01/jan/88 0,2
7H-Dibenzo[c,g]carbazole cancer SQE 194-59-2 01/jan/88 0.0030 (oral)
Dibenzo[a,e]pyrene cancer SQE 192-65-4 01/jan/88  
Dibenzo[a,h]pyrene cancer SQE 189-64-0 01/jan/88 0.0054 (oral)
Dibenzo[a,i]pyrene cancer SQE 189-55-9 01/jan/88 0.0050 (oral)
Dibenzo[a,l]pyrene cancer SQE 191-30-0 01/jan/88  
Dibromoacetic acid cancer AB 631-64-1 17/jun/08  
Dibromoacetonitrile cancer AB 3252-43-5 03/mai/11  
1,2-Dibromo-3-chloropropane  (DBCP) cancer FR 96-12-8 01/jul/87 0,1
1,2-Dibromo-3-chloropropane  (DBCP) male LC 96-12-8 27/fev/87 3.1 (oral)                          4.3 (inhalation) 
2,3-Dibromo-1-propanol cancer AB 96-13-9 01/out/94  
Dichloroacetic acid cancer AB 79-43-6 01/mai/96  
Dichloroacetic acid male LC 79-43-6 07/ago/09  
p-Dichlorobenzene cancer SQE 106-46-7 01/jan/89 20
3,3'-Dichlorobenzidine cancer SQE 91-94-1 01/out/87 0,6
3,3'-Dichlorobenzidine dihydrochloride cancer  AB 612-83-9 15/mai/98  
1,1-Dichloro-2,2-bis(p-chloropheny)ethylene (DDE) developmental, male  AB 72-55-9 30/mar/10  
1,4-Dichloro-2-butene cancer AB 764-41-0 01/jan/90  
3,3'-Dichloro-4,4'-diamino-diphenyl ether cancer SQE 28434-86-8 01/jan/88  
1,1-Dichloroethane cancer AB 75-34-3 01/jan/90 100
Dichloromethane (Methylene chloride) cancer SQE 75-09-2 01/abr/88 50                                    200 (inhalation)
Dichlorophene developmental  AB 97-23-4 27/abr/99  
Dichlorphenamide developmental  FR 120-97-8 27/fev/01  
Diclofop-methyl cancer  AB 51338-27-3 06/abr/10  
Diclofop methyl developmental  AB 51338-27-3 05/mar/99  
1,2-Dichloropropane cancer AB 78-87-5 01/jan/90 9,7
1,3-Dichloro-2-propanol (1,3-DCP) cancer SQE 96-23-1 08/out/10  
1,3-Dichloropropene cancer SQE 542-75-6 01/jan/89  
Dicumarol developmental FR 66-76-2 01/out/92  
Dieldrin cancer SQE 60-57-1 01/jul/88 0,04
Dienestrol Delisted January 4, 2013 [Click here for the basis for delisting] cancer LC 84-17-3 01/jan/90  
Diepoxybutane cancer SQE 1464-53-5 01/jan/88  
Diesel engine exhaust cancer AB --- 01/out/90  
Diethanolamine cancer LC 111-42-2 22/jun/12  
Di(2-ethylhexyl)phthalate cancer SQE 117-81-7 01/jan/88 310
Di(2-ethylhexyl)phthalate developmental, male  AB 117-81-7 24/out/03  
   Adultb         4200 (intravenous)        
   Infant boys, age 29 days to 24 monthsb         600 (intravenous)
   Neonatal infant boys, age 0 to 28 daysb         210 (intravenous)
   Adultb         410 (oral)
   Infant boys, age 29 days to 24 monthsb         58 (oral)
   Neonatal infant boys, age 0 to 28 daysb         20 (oral)
1,2-Diethylhydrazine cancer SQE 1615-80-1 01/jan/88  
Diethylstilbestrol (DES)  cancer LC 56-53-1 27/fev/87 0,002
Diethylstilbestrol (DES)  developmental FR 56-53-1 01/jul/87  
Diethyl sulfate cancer SQE 64-67-5 01/jan/88  
Diflunisal developmental, female  FR 22494-42-4 29/jan/99  
Diglycidyl ether male  LC 2238-07-5 07/ago/09  
Diglycidyl resorcinol ether (DGRE) cancer SQE 101-90-6 01/jul/89 0,4
Dihydroergotamine mesylate  developmental  FR 6190-39-2 01/mai/97  
Dihydrosafrole cancer SQE 94-58-6 01/jan/88 20
Diisopropyl sulfate cancer AB 2973-10-6 01/abr/93  
Di-isodecyl phthalate (DIDP) developmental  AB 68515-49-1/      26761-40-0 20/abr/07 2200
Diltiazem hydrochloride  developmental  FR 33286-22-5 27/fev/01  
3,3'-Dimethoxybenzidine (o-Dianisidine) cancer SQE 119-90-4 01/jan/88 0,15
3,3'-Dimethoxybenzidine dihydrochloride cancer AB 20325-40-0 01/out/90 0,19
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine cancer  AB  --- 11/jun/04  
N,N-Dimethylacetamide developmental    LC 127-19-5 21/mai/10  
4-Dimethylaminoazobenzene cancer SQE 60-11-7 01/jan/88 0,2
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole cancer SQE 55738-54-0 01/jan/88 2
7,12-Dimethylbenz(a)anthracene cancer AB 57-97-6 01/jan/90 0,003
3,3'-Dimethylbenzidine (ortho-Tolidine) cancer SQE 119-93-7 01/jan/88 0,044
3,3'-Dimethylbenzidine dihydrochloride cancer AB 612-82-8 01/abr/92 0,059
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine cancer  AB  --- 11/jun/04  
Dimethylcarbamoyl chloride cancer SQE 79-44-7 01/jan/88 0,05
1,1-Dimethylhydrazine (UDMH) cancer LC 57-14-7 01/out/89  
1,2-Dimethylhydrazine cancer SQE 540-73-8 01/jan/88 0,001
2,6-Dimethyl-N-nitrosomorpholine (DMNM) cancer SQE 1456-28-6 08/fev/13  
Dimethyl sulfate cancer SQE 77-78-1 01/jan/88  
Dimethylvinylchloride cancer SQE 513-37-1 01/jul/89 20
Di-n-butyl phthalate (DBP) developmental, female, male  AB 84-74-2 02/dez/05 8,7
Di-n-hexyl phthalate (DnHP) female, male  AB 84-75-3 02/dez/05 2200 (oral)
m-Dinitrobenzene male AB 99-65-0 01/jul/90 38
o-Dinitrobenzene male AB 528-29-0 01/jul/90  
p-Dinitrobenzene male AB 100-25-4 01/jul/90  
3,7-Dinitrofluoranthene cancer  AB 105735-71-5 26/ago/97  
3,9-Dinitrofluoranthene cancer  AB 22506-53-2 26/ago/97  
1,3-Dinitropyrene cancer LC 75321-20-9 02/nov/12  
1,6-Dinitropyrene cancer AB 42397-64-8 01/out/90  
1,8-Dinitropyrene cancer AB 42397-65-9 01/out/90  
2,4-Dinitrotoluene cancer SQE 121-14-2 01/jul/88 2
2,4-Dinitrotoluene male  AB 121-14-2 20/ago/99  
2,6-Dinitrotoluene cancer SQE 606-20-2 01/jul/95  
2,6-Dinitrotoluene male  AB 606-20-2 20/ago/99  
Dinitrotoluene (technical grade) female, male  AB --- 20/ago/99  
Dinitrotoluene mixture, 2,4-/2,6- cancer AB --- 01/mai/96  
Dinocap developmental FR 39300-45-3 01/abr/90  
Dinoseb developmental, male FR 88-85-7 01/jan/89  
Di-n-propyl isocinchomeronate (MGK Repellent 326) cancer AB 136-45-8 01/mai/96  
1,4-Dioxane cancer SQE 123-91-1 01/jan/88 30
Diphenylhydantoin (Phenytoin) cancer SQE 57-41-0 01/jan/88  
Diphenylhydantoin (Phenytoin) developmental SQE 57-41-0 01/jul/87  
Diphenylhydantoin (Phenytoin), sodium salt cancer SQE 630-93-3 01/jan/88  
Direct Black 38 (technical grade) cancer SQE 1937-37-7 01/jan/88 0,09
Direct Blue 6 (technical grade) cancer SQE 2602-46-2 01/jan/88 0,09
Direct Brown 95 (technical grade) cancer SQE 16071-86-6 01/out/88 0,1
Disodium cyanodithioimidocarbonate developmental  AB 138-93-2 30/mar/99 56 (oral)                           170 (oral) as 32% pesticidal formulation
Disperse Blue 1 cancer AB 2475-45-8 01/out/90 200
Diuron cancer AB 330-54-1 31/mai/02  
Doxorubicin hydrochloride (Adriamycin) cancer SQE 25316-40-9 01/jul/87  
Doxorubicin hydrochloride (Adriamycin) developmental, male  FR 25316-40-9 29/jan/99  
Doxycycline (internal use) developmental FR 564-25-0 01/jul/90  
Doxycycline calcium (internal use) developmental FR 94088-85-4 01/jan/92  
Doxycycline hyclate (internal use) developmental FR 24390-14-5 01/out/91  
Doxycycline monohydrate (internal use) developmental FR 17086-28-1 01/out/91  
           
Endrin  developmental  AB 72-20-8 15/mai/98  
Environmental tobacco smoke (ETS) developmental SQE   --- 09/jun/06  
Epichlorohydrin cancer SQE 106-89-8 01/out/87 9
Epichlorohydrin male AB 106-89-8 01/set/96  
Epoxiconazole cancer AB 135319-73-2 15/abr/11  
Ergotamine tartrate  developmental FR 379-79-3 01/abr/90  
Erionite cancer SQE 12510-42-8; 66733-21-9 01/out/88  
Estradiol 17B cancer SQE 50-28-2 01/jan/88 0,02
Estragole cancer SQE 140-67-0 29/out/99  
Estrogens, steroidal cancer LC   --- 19/ago/05  
Estrogen-progestogen (combined) used as menopausal therapy cancer LC  --- 04/nov/11  
Estrone cancer SQE 53-16-7 01/jan/88  
Estropipate  cancer, developmental  FR 7280-37-7 26/ago/97  
Ethanol in alcoholic beverages cancer LC  --- 29/abr/11  
Ethinylestradiol cancer SQE 57-63-6 01/jan/88  
Ethionamide  developmental FR 536-33-4 26/ago/97  
Ethoprop cancer  AB 13194-48-4 27/fev/01  
Ethyl acrylate cancer SQE 140-88-5 01/jul/89  
Ethyl alcohol in alcoholic beverages developmental SQE --- 01/out/87  
Ethylbenzene cancer  AB 100-41-4 11/jun/04 54 (inhalation)                 41 (oral)
Ethyl-tert-butyl ether male  LC 637-92-3 18/dez/09  
Ethyl dipropylthiocarbamate  developmental  AB 759-94-4 27/abr/99 700 (oral and inhalation)              6700 (dermal)
Ethyl-4,4'-dichlorobenzilate cancer AB 510-15-6 01/jan/90 7
Ethylene dibromide  cancer FR 106-93-4 01/jul/87 0.2 (oral)                          3 (inhalation)
Ethylene dibromide  developmental, male  AB 106-93-4 15/mai/98  
Ethylene dichloride (1,2-Dichloroethane) cancer SQE 107-06-2 01/out/87 10
Ethylene glycol monoethyl ether developmental, male SQE 110-80-5 01/jan/89 750 (oral)                         960 (inhalation)
Ethylene glycol monoethyl ether acetate developmental, male AB 111-15-9 01/jan/93 1100 (oral)                       1400 (inhalation)
Ethylene glycol monomethyl ether developmental, male SQE 109-86-4 01/jan/89 63 (oral)
Ethylene glycol monomethyl ether acetate developmental, male AB 110-49-6 01/jan/93 98 (oral)
Ethyleneimine cancer SQE 151-56-4 01/jan/88 0,01
Ethylene oxide cancer FR 75-21-8 01/jul/87 2
Ethylene oxide female LC 75-21-8 27/fev/87 20
Ethylene oxide developmental, male  LC 75-21-8 07/ago/09  
Ethylene thiourea cancer AB 96-45-7 01/jan/88 20
Ethylene thiourea developmental SQE 96-45-7 01/jan/93  
2-Ethylhexanoic acid developmental  LC 149-57-5 07/ago/09  
Ethyl methanesulfonate cancer SQE 62-50-0 01/jan/88  
Etodolac developmental, female   FR 41340-25-4 20/ago/99  
Etoposide cancer LC 33419-42-0 04/nov/11  
Etoposide developmental FR 33419-42-0 01/jul/90  
Etoposide in combination with cisplatin and bleomycin cancer LC  --- 04/nov/11  
Etretinate developmental SQE 54350-48-0 01/jul/87  
           
Fenoxaprop ethyl developmental  AB 66441-23-4  26/mar/99  
Fenoxycarb cancer  AB 72490-01-8 02/jun/00  
Filgrastim developmental  FR 121181-53-1 27/fev/01  
Fluazifop butyl developmental  AB 69806-50-4 06/nov/98  
Flunisolide developmental, female  FR 3385-03-3 15/mai/98  
Fluorouracil developmental SQE 51-21-8 01/jan/89  
Fluoxymesterone developmental FR 76-43-7 01/abr/90  
Flurazepam hydrochloride developmental FR 1172-18-5 01/out/92  
Flurbiprofen developmental, female  FR 5104-49-4 20/ago/99  
Flutamide developmental FR 13311-84-7 01/jul/90  
Fluticasone propionate developmental  FR 80474-14-2 15/mai/98  
Fluvalinate developmental  AB 69409-94-5 06/nov/98  
Folpet cancer SQE 133-07-3 01/jan/89 200
Formaldehyde (gas) cancer SQE 50-00-0 01/jan/88 40
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole cancer SQE 3570-75-0 01/jan/88 0,3
Fumonisin B1 cancer AB 116355-83-0 14/nov/03  
Furan cancer AB 110-00-9 01/out/93  
Furazolidone cancer AB 67-45-8 01/jan/90  
Furmecyclox cancer AB 60568-05-0 01/jan/90 20
Fusarin C cancer SQE 79748-81-5 01/jul/95  
           
Gallium arsenide cancer  LC 1303-00-0 01/ago/08  
Ganciclovir cancer, developmental, male  FR 82410-32-0 26/ago/97  
Ganciclovir sodium developmental, male  FR 107910-75-8 26/ago/97  
Gasoline engine exhaust (condensates/extracts) cancer AB --- 01/out/90  
Gemfibrozil cancer FR 25812-30-0 22/dez/00  
Gemfibrozil female, male  FR 25812-30-0 20/ago/99  
Glass wool fibers (inhalable and biopersistent) cancer AB --- 01/jul/90  
Glu-P-1 (2-Amino-6-methyldipyrido[1,2- a:3',2'-d]imidazole) cancer AB 67730-11-4 01/jan/90 0,1
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole) cancer AB 67730-10-3 01/jan/90 0,5
Glycidaldehyde cancer SQE 765-34-4 01/jan/88  
Glycidol cancer AB 556-52-5 01/jul/90 0,54
Goserelin acetate developmental, female, male  FR 65807-02-5 26/ago/97  
Griseofulvin cancer AB 126-07-8 01/jan/90  
Gyromitrin (Acetaldehyde methylformylhydrazone) cancer SQE 16568-02-8 01/jan/88 0,07
           
Halazepam developmental FR 23092-17-3 01/jul/90  
Halobetasol propionate developmental  FR 66852-54-8 20/ago/99  
Haloperidol developmental, female  FR 52-86-8 29/jan/99  
Halothane developmental FR 151-67-7 01/set/96  
HC Blue 1 cancer SQE 2784-94-3 01/jul/89 10
Heptachlor cancer SQE 76-44-8 01/jul/88 0,2
Heptachlor developmental AB 76-44-8 20/ago/99  
Heptachlor epoxide cancer SQE 1024-57-3 01/jul/88 0,08
Herbal remedies containing plant species of the genus Aristolochia cancer  LC   --- 09/jul/04  
Hexachlorobenzene cancer SQE 118-74-1 01/out/87 0,4
Hexachlorobenzene developmental SQE 118-74-1 01/jan/89  
Hexachlorobutadiene cancer AB 87-68-3 03/mai/11  
Hexachlorocyclohexane (technical grade) cancer SQE --- 01/out/87 0,2
   Hexachlorocyclohexane (alpha isomer)         0,3
   Hexachlorocyclohexane (beta isomer)         0,5
   Hexachlorocyclohexane (gamma isomer)         0,6
Hexachlorodibenzodioxin cancer SQE 34465-46- 8 01/abr/88 0,0002
Hexachloroethane cancer AB 67-72-1 01/jul/90 20
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer) cancer AB   --- 04/mar/05  
Hexafluoroacetone male  LC 684-16-2 01/ago/08  
Hexamethylphosphoramide cancer SQE 680-31-9 01/jan/88  
Hexamethylphosphoramide male AB 680-31-9 01/out/94  
Histrelin acetate developmental  FR --- 15/mai/98  
Hydramethylnon developmental, male  AB 67485-29-4 05/mar/99 120 (oral)
Hydrazine cancer SQE 302-01-2 01/jan/88 0,04
Hydrazine sulfate cancer SQE 10034-93-2 01/jan/88 0,2
Hydrazobenzene (1,2-Diphenylhydrazine) cancer SQE 122-66-7 01/jan/88 0,8
1-Hydroxyanthraquinone cancer LC 129-43-1 27/mai/05  
Hydroxyurea developmental  FR 127-07-1 01/mai/97  
           
Idarubicin hydrochloride developmental, male  FR 57852-57-0 20/ago/99  
Ifosfamide developmental FR 3778-73-2 01/jul/90  
Iodine-131 developmental SQE 10043-66-0 01/jan/89  
Imazalil cancer AB 35554-44-0 20/mai/11 11
Indeno [1,2,3-cd]pyrene cancer SQE 193-39-5 01/jan/88  
Indium phosphide cancer  AB 22398-80-7 27/fev/01  
IQ (2-Amino-3-methylimidazo[4,5-f] quinoline)  cancer AB 76180-96-6 01/abr/90 0,5
Iprodione cancer AB 36734-19-7 01/mai/96  
Iprovalicarb cancer  AB 140923-17-7 & 140923-25-7 01/jun/07  
Iron dextran complex cancer SQE 9004-66-4 01/jan/88  
Isobutyl nitrite cancer AB 542-56-3 01/mai/96 7,4
Isoprene cancer AB 78-79-5 01/mai/96  
Isopyrazam cancer AB 881685-58-1 24/jul/12  
Isosafrole Delisted December 8, 2006 [Click here for the basis for delisting] cancer LC     120-58-1 01/out/89  
Isotretinoin  developmental SQE 4759-48-2 01/jul/87  
Isoxaflutole cancer AB 141112-29-0 22/dez/00  
           
Kresoxim-methyl cancer AB 143390-89-0 03/fev/12  
           
Lactofen cancer SQE 77501-63-4 01/jan/89  
Lasiocarpine cancer SQE 303-34-4 01/abr/88 0,09
Lead developmental, female, male LC --- 27/fev/87 0,5
Lead and lead compounds cancer AB --- 01/out/92  
   Lead         15 (oral)
Lead acetate cancer SQE 301-04-2 01/jan/88 23 (oral)
Lead phosphate cancer SQE 7446-27-7 01/abr/88 58 (oral)
Lead subacetate cancer LC 1335-32-6 01/out/89 41 (oral)
Leather dust cancer LC  --- 29/abr/11  
Leuprolide acetate developmental, female, male  FR 74381-53-6 26/ago/97  
Levodopa developmental  FR 59-92-7 29/jan/99  
Levonorgestrel implants female  FR 797-63-7 15/mai/98  
Lindane and other hexachlorocyclohexane isomers cancer LC --- 01/out/89  
Linuron developmental  AB 330-55-2 19/mar/99 460
Lithium carbonate developmental FR 554-13-2 01/jan/91  
Lithium citrate developmental FR 919-16-4 01/jan/91  
Lorazepam developmental FR 846-49-1 01/jul/90  
Lovastatin developmental FR 75330-75-5 01/out/92  
Lynestrenol cancer  AB 52-76-6 27/fev/01  
           
Malonaldehyde, sodium salt cancer AB 24382-04-5 29/abr/11  
Mancozeb cancer AB 8018-01-7 01/jan/90  
Maneb cancer AB 12427-38-2 01/jan/90  
Marijuana smoke cancer SQE --- 19/jun/09  
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) cancer AB 68006-83-7 01/jan/90 0,6
Mebendazole developmental  FR 31431-39-7 20/ago/99  
Medroxyprogesterone acetate cancer AB 71-58-9 01/jan/90  
Medroxyprogesterone acetate developmental FR 71-58-9 01/abr/90  
Megestrol acetate developmental FR 595-33-5 01/jan/91  
MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) cancer AB 77094-11-2 01/out/94 0,46
MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) cancer AB 77500-04-0 01/out/94 0,41
Melphalan cancer LC 148-82-3 27/fev/87 0,005
Melphalan developmental FR 148-82-3 01/jul/90  
Menotropins developmental FR 9002-68-0 01/abr/90  
Mepanipyrim cancer  AB 110235-47-7 01/jul/08  
Meprobamate developmental FR 57-53-4 01/jan/92  
Mercaptopurine developmental FR 6112-76-1 01/jul/90  
Mercury and mercury compounds developmental AB --- 01/jul/90  
Merphalan cancer SQE 531-76-0 01/abr/88  
Mestranol cancer SQE 72-33-3 01/abr/88  
Metam potassium cancer AB 137-41-7 31/dez/10  
Methacycline hydrochloride developmental FR 3963-95-9 01/jan/91  
Metham sodium cancer  AB 137-42-8 06/nov/98  
Metham sodium developmental  AB 137-42-8 15/mai/98  
Methanol developmental AB 67-56-1 16/mar/12 47,000 (inhalation)  23,000 (oral)
Methazole developmental  AB 20354-26-1 01/dez/99  
Methimazole developmental FR 60-56-0 01/jul/90  
Methotrexate developmental SQE 59-05-2 01/jan/89  
Methotrexate sodium developmental FR 15475-56-6 01/abr/90  
5-Methoxypsoralen with ultraviolet A therapy cancer SQE 484-20-8 01/out/88  
8-Methoxypsoralen with ultraviolet A therapy cancer LC 298-81-7 27/fev/87  
2-Methylaziridine (Propyleneimine) cancer SQE 75-55-8 01/jan/88 0,028
Methylazoxymethanol cancer SQE 590-96-5 01/abr/88  
Methylazoxymethanol acetate cancer SQE 592-62-1 01/abr/88  
Methyl bromide, as a structural fumigant developmental FR 74-83-9 01/jan/93 810 (inhalation)
Methyl carbamate cancer  AB 598-55-0 15/mai/98 160
Methyl chloride developmental  AB 74-87-3 10/mar/00  
Methyl chloride male  LC 74-87-3 07/ago/09  
3-Methylcholanthrene cancer AB 56-49-5 01/jan/90 0,03
5-Methylchrysene cancer SQE 3697-24-3 01/abr/88 0.0084 (oral)
4,4'-Methylene bis(2-chloroaniline) cancer FR 101-14-4 01/jul/87 0,5
4,4'-Methylene bis(N,N-dimethyl)benzenamine cancer LC 101-61-1 01/out/89 20
4,4'-Methylene bis(2-methylaniline) cancer SQE 838-88-0 01/abr/88 0,8
4,4'-Methylenedianiline cancer SQE 101-77-9 01/jan/88 0,4
4,4'-Methylenedianiline dihydrochloride cancer SQE 13552-44-8 01/jan/88 0,6
Methyleugenol cancer  AB 93-15-2 16/nov/01  
Methylhydrazine and its salts cancer AB --- 01/jul/92  
   Methylhydrazine         0.058 (oral)                      0.090 (inhalation)
   Methylhydrazine sulfate         0,18
2-Methylimidazole cancer LC 693-98-1 22/jun/12  
4-Methylimidazole cancer AB 822-36-6 07/jan/11 29
Methyl iodide cancer SQE 74-88-4 01/abr/88  
Methyl isobutyl ketone cancer LC 108-10-1 04/nov/11  
Methyl isocyanate (MIC) developmental, female  SQE 624-83-9 12/nov/10  
Methyl isopropyl ketone developmental LC 563-80-4 17/fev/12  
Methyl mercury developmental SQE --- 01/jul/87  
Methylmercury compounds cancer AB --- 01/mai/96  
Methyl methanesulfonate cancer SQE 66-27-3 01/abr/88 7
Methyl n-butyl ketone male  LC 591-78-6 07/ago/09  
2-Methyl-1-nitroanthraquinone (of uncertain purity) cancer SQE 129-15-7 01/abr/88 0,2
N-Methyl-N'-nitro-N-nitrosoguanidine cancer  SQE 70-25-7 01/abr/88 0,08
N-Methylolacrylamide cancer AB 924-42-5 01/jul/90  
N-Methylpyrrolidone developmental AB 872-50-4 15/jun/01 3200 (inhalation)             17000 (dermal)
α-Methyl styrene (alpha-Methylstyrene) cancer LC 98-83-9 02/nov/12  
α-Methyl styrene female LC 98-83-9 29/jul/11  
Methyltestosterone developmental FR 58-18-4 01/abr/90  
Methylthiouracil cancer LC 56-04-2 01/out/89 2
Metiram cancer AB 9006-42-2 01/jan/90  
Metiram developmental  AB 9006-42-2 30/mar/99  
Metronidazole cancer SQE 443-48-1 01/jan/88  
Michler's ketone cancer SQE 90-94-8 01/jan/88 0,8
Midazolam hydrochloride developmental FR 59467-96-8 01/jul/90  
Minocycline hydrochloride (internal use) developmental FR 13614-98-7 01/jan/92  
Mirex cancer SQE 2385-85-5 01/jan/88 0,04
Misoprostol developmental FR 59122-46-2 01/abr/90  
Mitomycin C cancer SQE 50-07-7 01/abr/88 0,00009
Mitoxantrone hydrochloride developmental FR 70476-82-3 01/jul/90  
Molinate developmental, female, male  AB 2212-67-1 11/dez/09  
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane cancer AB 71526-07-3 22/mar/11  
MON 13900 (furilazole) cancer AB 121776-33-8 22/mar/11  
3-Monochloropropane-1,2-diol (3-MCDP) cancer SQE 96-24-2 08/out/10  
Monocrotaline cancer SQE 315-22-0 01/abr/88 0,07
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) cancer LC 113803-47-7 04/nov/11  
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)-amino]-2-oxazolidinone cancer SQE 139-91-3 01/abr/88 0,18
Mustard Gas cancer LC 505-60-2 27/fev/87  
MX (3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone) cancer SQE 77439-76-0 22/dez/00 0,11
Myclobutanil developmental, male  AB 88671-89-0 16/abr/99  
           
Nabam developmental  AB 142-59-6 30/mar/99  
Nafarelin acetate developmental FR 86220-42-0 01/abr/90  
Nafenopin cancer SQE 3771-19-5 01/abr/88  
Nalidixic acid cancer  AB 389-08-2 15/mai/98 28
Naphthalene cancer  AB 91-20-3 19/abr/02 5,8
1-Naphthylamine cancer LC 134-32-7 01/out/89  
2-Naphthylamine cancer LC 91-59-8 27/fev/87 0,4
Neomycin sulfate (internal use) developmental FR 1405-10-3 01/out/92  
Netilmicin sulfate developmental FR 56391-57-2 01/jul/90  
Nickel (Metallic) cancer LC 7440-02-0 01/out/89  
Nickel acetate cancer LC 373-02-4 01/out/89  
Nickel carbonate cancer LC 3333-67-3 01/out/89  
Nickel carbonyl  cancer SQE 13463-39-3 01/out/87  
Nickel carbonyl  developmental AB 13463-39-3 01/set/96  
Nickel compounds cancer  LC --- 07/mai/04  
Nickel hydroxide cancer LC 12054-48-7; 12125-56-3 01/out/89  
Nickelocene cancer LC 1271-28-9 01/out/89  
Nickel oxide cancer LC 1313-99-1 01/out/89  
Nickel refinery dust from the pyrometallurgical process cancer SQE --- 01/out/87 0,8
Nickel subsulfide cancer SQE 12035-72-2 01/out/87 0,4
Nicotine developmental  FR 54-11-5 01/abr/90  
Nifedipine developmental, female, male  FR 21829-25-4 29/jan/99  
Nimodipine developmental  FR 66085-59-4 24/abr/01  
Niridazole cancer SQE 61-57-4 01/abr/88  
Nitrapyrin cancer  AB 1929-82-4 05/out/05  
Nitrapyrin developmental  AB 1929-82-4 30/mar/99  
Nitrilotriacetic acid cancer SQE 139-13-9 01/jan/88 100
Nitrilotriacetic acid, trisodium salt monohydrate cancer SQE 18662-53-8 01/abr/89 70
5-Nitroacenaphthene cancer SQE 602-87-9 01/abr/88 6
5-Nitro-o-anisidine Delisted December 8, 2006 [Click here for the basis for delisting] cancer LC 99-59-2 01/out/89 10
o-Nitroanisole cancer AB 91-23-6 01/out/92  
Nitrobenzene cancer  AB 98-95-3 26/ago/97  
Nitrobenzene male  AB 98-95-3 30/mar/10  
4-Nitrobiphenyl cancer SQE 92-93-3 01/abr/88  
6-Nitrochrysene cancer AB 7496-02-8 01/out/90  
Nitrofen (technical grade) cancer SQE 1836-75-5 01/jan/88 9
2-Nitrofluorene cancer AB 607-57-8 01/out/90  
Nitrofurantoin male AB 67-20-9 01/abr/91  
Nitrofurazone cancer AB 59-87-0 01/jan/90 0,5
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone cancer SQE 555-84-0 01/abr/88 0,4
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide cancer SQE 531-82-8 01/abr/88 0,5
Nitrogen mustard (Mechlorethamine) cancer SQE 51-75-2 01/jan/88  
Nitrogen mustard (Mechlorethamine) developmental SQE 51-75-2 01/jan/89  
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride) cancer SQE 55-86-7 01/abr/88  
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride) developmental FR 55-86-7 01/jul/90  
Nitrogen mustard N-oxide cancer SQE 126-85-2 01/abr/88  
Nitrogen mustard N-oxide hydrochloride cancer SQE 302-70-5 01/abr/88  
Nitromethane  cancer  AB 75-52-5 01/mai/97 39
2-Nitropropane cancer SQE 79-46-9 01/jan/88  
1-Nitropyrene cancer AB 5522-43-0 01/out/90  
4-Nitropyrene cancer AB 57835-92-4 01/out/90  
N-Nitrosodiethanolamine cancer SQE 1116-54-7 01/jan/88 0,3
N-Nitrosodiethylamine cancer SQE 55-18-5 01/out/87 0,02
N-Nitrosodimethylamine cancer SQE 62-75-9 01/out/87 0,04
N-Nitrosodi-n-butylamine cancer SQE 924-16-3 01/out/87 0,06
N-Nitrosodi-n-propylamine cancer SQE 621-64-7 01/jan/88 0,1
p-Nitrosodiphenylamine cancer SQE 156-10-5 01/jan/88 30
N-Nitrosodiphenylamine cancer SQE 86-30-6 01/abr/88 80
3-(N-Nitrosomethylamino) propionitrile cancer AB 60153-49-3 01/abr/90  
4-(N-Nitrosomethylamino)-1-(3-pyridyl)1-butanone cancer AB 64091-91-4 01/abr/90 0,014
N-Nitrosomethylethylamine cancer LC 10595-95-6 01/out/89 0,03
N-Nitrosomethylvinylamine cancer SQE 4549-40-0 01/jan/88  
N-Nitrosomorpholine cancer SQE 59-89-2 01/jan/88 0,1
N-Nitroso-N-ethylurea cancer SQE 759-73-9 01/out/87 0,03
N-Nitroso-N-methylurea cancer SQE 684-93-5 01/out/87 0,006
N-Nitroso-N-methylurethane cancer SQE 615-53-2 01/abr/88 0,006
N-Nitrosonornicotine cancer SQE 16543-55-8 01/jan/88 0,5
N-Nitrosopiperidine cancer SQE 100-75-4 01/jan/88 0,07
N-Nitrosopyrrolidine cancer SQE 930-55-2 01/out/87 0,3
N-Nitrososarcosine cancer SQE 13256-22-9 01/jan/88  
o-Nitrotoluene cancer  AB 88-72-2 15/mai/98  
Nitrous oxide developmental  LC 10024-97-2 01/ago/08  
Norethisterone (Norethindrone)  cancer LC 68-22-4 01/out/89  
Norethisterone (Norethindrone)  developmental FR 68-22-4 01/abr/90  
Norethisterone acetate (Norethindrone acetate) developmental FR 51-98-9 01/out/91  
Norethisterone (Norethindrone) /Ethinyl estradiol developmental FR 68-22-4               57-63-6 01/abr/90  
Norethisterone (Norethindrone) /Mestranol developmental FR 68-22-4           72-33-3 01/abr/90  
Norethynodrel cancer  AB 68-23-5 27/fev/01  
Norgestrel developmental FR 6533-00-2 01/abr/90  
           
Ochratoxin A cancer AB 303-47-9 01/jul/90  
Oil Orange SS cancer SQE 2646-17-5 01/abr/88  
Oral contraceptives, combined cancer LC --- 01/out/89  
Oral contraceptives, sequential cancer LC --- 01/out/89  
Oryzalin cancer AB 19044-88-3 12/set/08  
Oxadiazon cancer SQE 19666-30-9 01/jul/91  
Oxadiazon developmental  AB 19666-30-9 15/mai/98  
Oxazepam  cancer AB 604-75-1 01/out/94  
Oxazepam  developmental FR 604-75-1 01/out/92  
p,p'-Oxybis(benzenesulfonyl hydrazide) developmental  LC 80-51-3 07/ago/09  
Oxydemeton methyl female, male  AB 301-12-2 06/nov/98  
Oxymetholone  cancer SQE 434-07-1 01/jan/88  
Oxymetholone  developmental  FR 434-07-1 01/mai/97  
Oxytetracycline (internal use) developmental FR 79-57-2 01/jan/91  
Oxytetracycline hydrochloride (internal use) developmental FR 2058-46-0 01/out/91  
Oxythioquinox (Chinomethionat) cancer  AB 2439-01-2 20/ago/99  
Oxythioquinox (Chinomethionat) developmental  AB 2439-01-2 06/nov/98  
           
Paclitaxel developmental, female, male  FR 33069-62-4 26/ago/97  
Palygorskite fibers (> 5mm in length) cancer  AB 12174-11-7 28/dez/99  
Panfuran S cancer SQE 794-93-4 01/jan/88  
Paramethadione developmental FR 115-67-3 01/jul/90  
Penicillamine developmental FR 52-67-5 01/jan/91  
Pentachlorophenol cancer AB 87-86-5 01/jan/90 40
Pentobarbital sodium developmental FR 57-33-0 01/jul/90  
Pentostatin developmental FR 53910-25-1 01/set/96  
Phenacemide developmental FR 63-98-9 01/jul/90  
Phenacetin cancer LC 62-44-2 01/out/89 300
Phenazopyridine cancer SQE 94-78-0 01/jan/88 4
Phenazopyridine hydrochloride cancer SQE 136-40-3 01/jan/88 5
Phenesterin cancer SQE 3546-10-9 01/jul/89 0,005
Phenobarbital cancer AB 50-06-6 01/jan/90 2
Phenolphthalein cancer   AB 77-09-8 15/mai/98  
Phenoxybenzamine cancer SQE 59-96-1 01/abr/88 0,2
Phenoxybenzamine hydrochloride cancer SQE 63-92-3 01/abr/88 0,3
Phenprocoumon developmental FR 435-97-2 01/out/92  
o-Phenylenediamine and its salts cancer  AB 95-54-5 15/mai/98  
   o-Phenylenediamine         26
   o-Phenylenediamine dihydochloride         44
Phenyl glycidyl ether cancer AB 122-60-1 01/out/90 5
Phenyl glycidyl ether male  LC 122-60-1 07/ago/09  
Phenylhydrazine and its salts cancer AB --- 01/jul/92  
   Phenylhydrazine         1
   Phenylhydrazine hydrochloride         1,4
o-Phenylphenate, sodium cancer AB 132-27-4 01/jan/90 200
o-Phenylphenol cancer AB 90-43-7 04/ago/00  
Phenylphosphine developmental  LC 638-21-1 07/ago/09  
PhiP(2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine) cancer AB 105650-23-5 01/out/94  
Pimozide developmental, female  FR 2062-78-4 20/ago/99  
Pipobroman developmental FR 54-91-1 01/jul/90  
Pirimicarb cancer  AB 23103-98-2 01/jul/08  
Plicamycin developmental FR 18378-89-7 01/abr/90  
Polybrominated biphenyls cancer SQE --- 01/jan/88 0,02
Polybrominated biphenyls developmental AB --- 01/out/94  
Polychlorinated biphenyls cancer LC --- 01/out/89 0,09
Polychlorinated biphenyls developmental SQE --- 01/jan/91  
Polychlorinated biphenyls (containing 60 or more percent percent chlorine by molecular weight) cancer SQE --- 01/jan/88  
Polychlorinated dibenzo-p-dioxins cancer FR --- 01/out/92  
Polychlorinated dibenzofurans cancer FR --- 01/out/92  
Polygeenan cancer SQE 53973-98-1 01/jan/88 1200
Ponceau MX cancer SQE 3761-53-3 01/abr/88 200
Ponceau 3R cancer SQE 3564-09-8 01/abr/88 40
Potassium bromate cancer AB 7758-01-2 01/jan/90 1
Potassium dimethyldithiocarbamate developmental  AB 128-03-0 30/mar/99 720
Pravastatin sodium developmental  FR 81131-70-6 03/mar/00  
Prednisolone sodium phosphate developmental  FR 125-02-0 20/ago/99  
Primidone cancer  AB 125-33-7 20/ago/99  
Procarbazine cancer SQE 671-16-9 01/jan/88 0,05
Procarbazine hydrochloride cancer SQE 366-70-1 01/jan/88 0,06
Procarbazine hydrochloride developmental FR 366-70-1 01/jul/90  
Procymidone cancer AB 32809-16-8 01/out/94  
Progesterone cancer SQE 57-83-0 01/jan/88  
Pronamide cancer AB 23950-58-5 01/mai/96  
Propachlor cancer  AB 1918-16-7 27/fev/01  
1,3-Propane sultone cancer SQE 1120-71-4 01/jan/88 0,3
Propargite cancer AB 2312-35-8 01/out/94  
Propargite developmental  AB 2312-35-8 15/jun/99  
beta-Propiolactone cancer SQE 57-57-8 01/jan/88 0,05
Propoxur cancer  AB 114-26-1 11/ago/06  
Propylene glycol mono-t-butyl ether cancer  AB 57018-52-7 11/jun/04  
Propylene oxide cancer SQE 75-56-9 01/out/88  
Propylthiouracil cancer SQE 51-52-5 01/jan/88 0,7
Propylthiouracil developmental FR 51-52-5 01/jul/90  
Pymetrozine cancer AB 123312-89-0 22/mar/11  
Pyridine cancer AB 110-86-1 17/mai/02  
Pyrimethamine developmental  FR 58-14-0 29/jan/99  
           
Quazepam developmental  FR 36735-22-5 26/ago/97  
Quinoline and its strong acid salts cancer SQE --- 24/out/97  
Quizalofop-ethyl male  SQE 76578-14-8 24/dez/99 590
           
Radionuclides cancer SQE --- 01/jul/89  
Reserpine cancer LC 50-55-5 01/out/89 0,06
Residual (heavy) fuel oils cancer AB --- 01/out/90  
Resmethrin cancer  AB 10453-86-8 01/jul/08  
Resmethrin developmental  AB 10453-86-8 06/nov/98  
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents.  (NOTE:  Retinol/retinyl esters are required and essential for maintenance of normal reproductive function.  The recommended daily level during pregnancy is 8,000 IU.) developmental SQE  --- 01/jul/89  
Ribavirin developmental FR 36791-04-5 01/abr/90  
Ribavirin male  FR 36791-04-5 27/fev/01  
Riddelliine cancer  LC 23246-96-0 03/dez/04  
Rifampin developmental, female  FR 13292-46-1 27/fev/01  
           
Saccharin  Delisted April 6, 2001  [Click here for the basis for delisting] cancer LC 81-07-2 01/out/89  
Saccharin, sodium  Delisted January 17, 2003 [Click here for the basis for delisting] cancer SQE 128-44-9 01/jan/88  
Safrole cancer SQE 94-59-7 01/jan/88 3
Salted fish, Chinese-style cancer LC  --- 29/abr/11  
Secobarbital sodium  developmental FR 309-43-3 01/out/92  
Selenium sulfide cancer LC 7446-34-6 01/out/89  
Sermorelin acetate developmental  FR --- 20/ago/99  
Shale-oils cancer AB 68308-34-9 01/abr/90  
Silica, crystalline (airborne particles of respirable size) cancer SQE --- 01/out/88  
Sodium dimethyldithiocarbamate developmental  AB 128-04-1 30/mar/99 23 (oral)                         58 (oral) as a 40% pesticidal formulation
Sodium fluoroacetate male  AB 62-74-8 06/nov/98  
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils) cancer LC --- 27/fev/87  
Spirodiclofen cancer AB 148477-71-8 08/out/10  
Spironolactone cancer  FR 52-01-7 01/mai/97  
Stanozolol cancer  FR 10418-03-8 01/mai/97  
Sterigmatocystin cancer SQE 10048-13-2 01/abr/88 0,02
Streptomycin sulfate developmental   3810-74-0 01/jan/91  
Streptozocin (streptozotocin) developmental, female, male  FR 18883-66-4 20/ago/99  
Streptozotocin (streptozocin) cancer SQE 18883-66-4 01/jan/88 0,006
Strong inorganic acid mists containing sulfuric acid cancer  AB --- 14/mar/03  
Styrene oxide cancer SQE 96-09-3 01/out/88 4
Sulfallate cancer SQE 95-06-7 01/jan/88 4
Sulfasalazine (salicylazosulfapyridine) cancer  AB 599-79-1 15/mai/98  
Sulfasalazine (salicylazosulfapyridine) male  FR 599-79-1 29/jan/99  
Sulfur dioxide developmental SQE 7446-09-5 29/jul/11  
Sulindac developmental, female  FR 38194-50-2 29/jan/99  
           
Talc containing asbestiform fibers cancer AB --- 01/abr/90  
Tamoxifen and its salts cancer SQE 10540-29-1 01/set/96  
Tamoxifen citrate developmental FR 54965-24-1 01/jul/90  
Temazepam developmental FR 846-50-4 01/abr/90  
Teniposide developmental FR 29767-20-2 01/set/96  
Terbacil developmental  AB 5902-51-2 18/mai/99  
Terrazole cancer AB 2593-15-9 01/out/94  
Testosterone and its esters cancer SQE 58-22-0 01/abr/88  
Testosterone cypionate developmental FR 58-20-8 01/out/91  
Testosterone enanthate developmental FR 315-37-7 01/abr/90  
3,3',4,4'-Tetrachloroazobenzene cancer AB 14047-09-7 24/jul/12  
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) cancer SQE 1746-01-6 01/jan/88 0,000005
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) developmental AB 1746-01-6 01/abr/91  
1,1,2,2-Tetrachloroethane cancer AB 79-34-5 01/jul/90 3
Tetrachloroethylene (Perchloroethylene) cancer SQE 127-18-4 01/abr/88 14
p-a,a,a-Tetrachlorotoluene cancer AB 5216-25-1 01/jan/90  
Tetracycline (internal use) developmental FR 60-54-8 01/out/91  
Tetracyclines (internal use) developmental FR --- 01/out/92  
Tetracycline hydrochloride (internal use) developmental FR 64-75-5 01/jan/91  
Tetrafluoroethylene cancer AB 116-14-3 01/mai/97  
Tetranitromethane cancer AB 509-14-8 01/jul/90 0,059
Thalidomide developmental SQE 50-35-1 01/jul/87  
Thioacetamide cancer SQE 62-55-5 01/jan/88 0,1
4,4'-Thiodianiline cancer SQE 139-65-1 01/abr/88 0,05
Thiodicarb cancer  AB 59669-26-0 20/ago/99  
Thioguanine developmental FR 154-42-7 01/jul/90  
Thiophanate methyl female, male  AB 23564-05-8 18/mai/99 600 (oral)
Thiouracil cancer  AB 141-90-2 11/jun/04  
Thiourea cancer SQE 62-56-6 01/jan/88 10
Thorium dioxide cancer LC 1314-20-1 27/fev/87  
Titanium dioxide (airborne, unbound particles of respirable size) cancer LC  --- 02/set/11  
Tobacco, oral use of smokeless products cancer SQE --- 01/abr/88  
Tobacco smoke cancer SQE --- 01/abr/88  
Tobacco smoke (primary) developmental, female, male SQE --- 01/abr/88  
Tobramycin sulfate developmental FR 49842-07-1 01/jul/90  
Toluene developmental SQE 108-88-3 01/jan/91 7000c
Toluene female  LC 108-88-3 07/ago/09  
Toluene diisocyanate cancer LC 26471-62-5 01/out/89 20
o-Toluidine cancer SQE 95-53-4 01/jan/88 4
o-Toluidine hydrochloride cancer SQE 636-21-5 01/jan/88 5
para-Toluidine  Delisted October 29, 1999 [Click here for the basis for delisting] cancer AB 106-49-0 01/jan/90  
Toxaphene (Polychlorinated camphenes) cancer SQE 8001-35-2 01/jan/88 0,6
Toxins derived from Fusarium moniliforme (Fusarium verticillioides) cancer  LC   --- 07/ago/09  
Treosulfan cancer LC 299-75-2 27/fev/87  
Triadimefon developmental, female, male  AB 43121-43-3 30/mar/99  
Triazolam developmental FR 28911-01-5 01/abr/90  
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF) cancer AB 78-48-8 25/fev/11  
Tributyltin methacrylate developmental  AB 2155-70-6 01/dez/99  
Trichlormethine (Trimustine hydrochloride) cancer AB 817-09-4 01/jan/92  
Trichloroethylene cancer SQE 79-01-6 01/abr/88 14 (oral)                           50 (inhalation)
2,4,6-Trichlorophenol cancer SQE 88-06-2 01/jan/88 10
1,2,3-Trichloropropane cancer AB 96-18-4 01/out/92  
Trientine hydrochloride developmental  FR 38260-01-4 27/fev/01  
Triforine developmental  AB 26644-46-2 18/jun/99  
1,3,5-Triglycidyl-s-triazinetrione male  LC 2451-62-9 07/ago/09  
Trilostane developmental FR 13647-35-3 01/abr/90  
Trimethadione developmental FR 127-48-0 01/jan/91  
2,4,5-Trimethylaniline and its strong acid salts cancer  SQE --- 24/out/97  
Trimethyl phosphate cancer AB 512-56-1 01/mai/96 24
Trimetrexate glucuronate developmental  FR 82952-64-5 26/ago/97  
2,4.6-Trinitrotoluene (TNT) cancer  SQE 118-96-7 19/dez/08 8,2
Triphenyltin hydroxide cancer AB 76-87-9 01/jul/92  
Triphenyltin hydroxide developmental  AB 76-87-9 18/mar/02  
Tris(aziridinyl)-p-benzoquinone (Triaziquone) Delisted December 8, 2006 [Click here for the basis for delisting] cancer LC 68-76-8 01/out/89  
Tris(1-aziridinyl)phosphine sulfide (Thiotepa) cancer SQE 52-24-4 01/jan/88 0,06
Tris(2-chloroethyl) phosphate cancer AB 115-96-8 01/abr/92  
Tris(2,3-dibromopropyl)phosphate cancer SQE 126-72-7 01/jan/88 0,3
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) cancer SQE 13674-87-8 28/out/11 5,4
Trp-P-1 (Tryptophan-P-1) cancer SQE 62450-06-0 01/abr/88 0,03
Trp-P-2 (Tryptophan-P-2) cancer SQE 62450-07-1 01/abr/88 0,2
Trypan blue (commercial grade) cancer LC 72-57-1 01/out/89  
           
Unleaded gasoline (wholly vaporized) cancer SQE --- 01/abr/88  
Uracil mustard cancer SQE 66-75-1 01/abr/88  
Uracil mustard developmental, female, male FR 66-75-1 01/jan/92  
Urethane (Ethyl carbamate) cancer SQE 51-79-6 01/jan/88 0,7
Urethane (Ethyl carbamate) developmental AB 51-79-6 01/out/94  
Urofollitropin developmental FR 97048-13-0 01/abr/90  
           
Valproate (Valproic acid) developmental SQE 99-66-1 01/jul/87  
Vanadium pentoxide (orthorhombic crystalline form) cancer  AB 1314-62-1 11/fev/05  
Vinblastine sulfate developmental FR 143-67-9 01/jul/90  
Vinclozolin cancer  AB 50471-44-8 20/ago/99  
Vinclozolin developmental  AB 50471-44-8 15/mai/98  
Vincristine sulfate developmental FR 2068-78-2 01/jul/90  
Vinyl bromide cancer SQE 593-60-2 01/out/88  
Vinyl chloride cancer LC 75-01-4 27/fev/87 3
4-Vinylcyclohexene cancer AB 100-40-3 01/mai/96  
4-Vinylcyclohexene female, male   LC 100-40--3 07/ago/09  
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexenedioxide) cancer AB 106-87-6 01/jul/90  
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide) female, male  LC 106-87-6 01/ago/08  
Vinyl fluoride cancer AB 75-02-5 01/mai/97  
Vinyl trichloride (1,1,2-Trichloroethane) cancer AB 79-00-5 01/out/90 10
           
Warfarin developmental SQE 81-81-2 01/jul/87  
Wood dust cancer  LC  --- 18/dez/09  
           
2,6-Xylidine (2,6-Dimethylaniline) cancer AB 87-62-7 01/jan/91 110
           
Zalcitabine cancer  LC 7481-89-2 07/ago/09  
Zidovudine (AZT) cancer  LC 30516-87-1 18/dez/09  
Zileuton  cancer, developmental, female FR 111406-87-2 22/dez/00  
Zineb  Delisted October 29, 1999 [Click here for the basis for delisting] cancer AB 12122-67-7 01/jan/90  
a Where a source or product results in exposures by multiple routes, the total exposure must be considered.  For example, the MADL for benzene is exceeded when the absorbed dose exceeds 24 µg/day.  If only inhalation and oral exposure occurs, the benzene MADL is exceeded when:  (oral dose ÷ 24 µg/day) + (inhalation dose ÷ 49 µg/day) > 1.0.
b Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803
c Level represents absorbed dose (rounded from 6,525 µg/day ).  Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose.  It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed.  Therefore the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day ), corresponding to an absorbed dose of 6,525 µg/day.






Nenhum comentário:

Postar um comentário